Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205

od Li, T., Christos, P. J., Sparano, J. A., Hershman, D. L., Hoschander, S., O'Brien, K., Wright, J. J., Vahdat, L. T.
Izdano 2009

Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary†‡

od Chuang, E., Wiener, N., Christos, P., Kessler, R., Cobham, M., Donovan, D., Goldberg, G. L., Caputo, T., Doyle, A., Vahdat, L., Sparano, J. A.
Izdano 2010

Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse

od Jain, S., Cohen, J., Ward, M. M., Kornhauser, N., Chuang, E., Cigler, T., Moore, A., Donovan, D., Lam, C., Cobham, M. V., Schneider, S., Hurtado Rúa, S. M., Benkert, S., Mathijsen Greenwood, C., Zelkowitz, R., Warren, J. D., Lane, M. E., Mittal, V., Rafii, S., Vahdat, L. T.
Izdano 2013

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer

od Chung, J H, Pavlick, D, Hartmaier, R, Schrock, A B, Young, L, Forcier, B, Ye, P, Levin, M K, Goldberg, M, Burris, H, Gay, L M, Hoffman, A D, Stephens, P J, Frampton, G M, Lipson, D M, Nguyen, D M, Ganesan, S, Park, B H, Vahdat, L T, Leyland-Jones, B, Mughal, T I, Pusztai, L, O’Shaughnessy, J, Miller, V A, Ross, J S, Ali, S M
izdano v Ann Oncol (2017)